In its first-quarter 2026 investor letter, TimesSquare Capital U.S.
Mid Cap Growth Strategy highlighted Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a US based commercial-stage biotechnology company, that develops and provides RNA-targeted medicines. On July 1, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) closed at $79.19 per share, reflecting a market capitalization of $13.09 billion. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted a one-month return of 5.40%, and its shares gained 84.16% over the past 52 weeks.
TimesSquare Capital U.S. Mid Cap Growth Strategy stated the following regarding Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in its Q1 2026 investor letter: “Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that command premium pricing, or specialized service providers. New to the sector this quarter was Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a commercial-stage biotechnology company focused on neurology and cardiovascular indications.